As of September 7, 2026, micro- and nano-robotics has advanced in commercial catheter systems, robotic microsurgery, drug delivery, cell therapy, and miniature-machine control. The key takeaway is that human-facing products remain larger robotic instruments, while true micro- and nanoscale therapies are still laboratory or animal research. "Microrobot" and "nanorobot" describe extremely small devices designed to move, manipulate objects, deliver payloads, or respond to external control. The label covers very different technologies, so size, operating environment, and evidence level matter more than the word "robot.".
Table of Contents
- Which systems are moving into clinical use?
- What are the strongest medical research results?
- Can nanorobots manufacture drugs at their destination?
- What changed in movement and control?
- How should readers judge new nanorobot claims?
Which systems are moving into clinical use?
microbot Medical began the U.S. full-market release of LIBERTY, its FDA-cleared, single-use, remotely operated endovascular system. By May, hospitals in six states had adopted it, according to Microbot Medical's May 14 release. This is the clearest documented commercial scale-up in the field during 2026.
However, LIBERTY is catheter robotics for procedures inside blood vessels, not an autonomous or free-swimming nanobot. Medical Microinstruments also advanced a human study involving its Symani robotic microsurgery system. An FDA investigational-device supplement expanded the REMIND early-feasibility study from up to five patients to 15 after a 30-day safety review. Surgeons use Symani to restore cervical lymphatic drainage as researchers explore a possible application related to Alzheimer's disease. The expanded study permits more investigation; it does not establish that the procedure treats brain disease.
What are the strongest medical research results?
ETH Zurich and the University of Zurich reported 6-micrometre magnetoelectric "NPCbots." These devices carried neural progenitor cells and provided wireless stimulation. Treated zebrafish approached normal swimming within three days, while mice improved after spinal-cord transection, according to ETH Zurich's June research report. These are promising animal results, but they do not demonstrate safety or benefit in humans.
University of Hong Kong researchers used near-infrared, or NIR-II, fluorescence to follow magnetic nanorobots inside living mice. The system delivered 5-aminosalicylic acid to the lower gut and improved efficacy in an inflammatory-bowel-disease model. The practical advance is feedback: researchers could see where the robots traveled instead of steering without live positional information. Human translation has not been demonstrated.
Can nanorobots manufacture drugs at their destination?
University of Basel researchers created reusable nanorobots assembled from DNA components. Magnetic control moved the devices, while enzyme payloads produced an anticancer drug locally. In experiments involving HeLa cells, the treatment reduced cell viability to 16% after 72 hours, according to the University of Basel report.
This suggests a route toward localized chemical production rather than simply transporting a finished drug. The result remains a cell experiment. Before medical use, researchers would still need evidence that such devices can reach the intended tissue, operate reliably, avoid harmful reactions, and leave the body safely.
What changed in movement and control?
A Nature Communications team introduced sub-millimetre acoustic "ECHObots" with engineered cilia. Sound energy lets these hair-like structures produce bending, rotation, opening, closing, and broader shape changes. Machine-learning-assisted design reduced prediction time by more than 100,000-fold, the researchers reported in the March 12 Nature Communications study.
Faster design could help engineers test useful movements without relying on slow trial-and-error development. A separate study demonstrated sub-micrometre, light-driven robots with plasmonic antennas. These structures combined propulsion with orientation control and could collect and transport bacteria. That work demonstrates laboratory manipulation, not a clinical system for removing infections or cleaning the body.
How should readers judge new nanorobot claims?
The most important distinction is the development stage. An FDA-cleared catheter robot, an early human feasibility study, an animal experiment, and a cell-culture result provide very different levels of evidence.
When assessing a release or paper, check: As of September 7, the evidence does not support treating therapeutic nanorobots as near-term routine medicine. The strongest nanoscale medical findings remain in cells or animals, while current human developments rely on robotic microsurgery and endovascular systems.
- Scale: Is it a robotic catheter, a micrometre-scale device, or a nanoscale structure?
- Setting: Was it tested in cells, animals, healthy volunteers, or patients?
- Control: Does it use magnetic fields, sound, light, or remote mechanical operation?
- Outcome: Did researchers show movement, payload delivery, biological improvement, or clinical benefit?
- Status: Is it commercially released, cleared for a specific use, under investigation, or purely experimental?
You Might Also Like
- What Is New With Tutorials and DIY Robotics in September 2026? Latest company releases and research papers and Key Takeaways
- What Is New With Education Robotics in September 2026? Latest company releases and research papers and Key Takeaways
- What Is New With Construction Robotics in September 2026? Latest company releases and research papers and Key Takeaways
